Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/1999

01-03-1999

Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse

Authors: Nadia Harbeck, Christoph Thomssen, Ursula Berger, Kurt Ulm, Ronald E. Kates, Heinz Höfler, Fritz Jänicke, Henner Graeff, Manfred Schmitt

Published in: Breast Cancer Research and Treatment | Issue 2/1999

Login to get access
Metadata
Title
Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse
Authors
Nadia Harbeck
Christoph Thomssen
Ursula Berger
Kurt Ulm
Ronald E. Kates
Heinz Höfler
Fritz Jänicke
Henner Graeff
Manfred Schmitt
Publication date
01-03-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006118828278

Other articles of this Issue 2/1999

Breast Cancer Research and Treatment 2/1999 Go to the issue

OriginalPaper

Vitamin D3 receptor (VDR) expression in HC‐11 mammary cells: regulation by growth‐modulatory agents, differentiation, and Ha‐ras transformation

OriginalPaper

Tumour necrosis factor‐α and interleukin‐1 and ‐6 in fibrocystic breast disease

OriginalPaper

Constitutive activation of pp125fak in newly isolated human breast cancer cell lines

OriginalPaper

The additionally glycosylated variant of human sex hormone‐binding globulin (SHBG) is linked to estrogen‐dependence of breast cancer

OriginalPaper

De‐regulation of GRP stress protein expression in human breast cancer cell lines

OriginalPaper

Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits